Corbus Pharmaceuticals Holdings Inc represents values of integrity, innovation, and dedication to improving patient outcomes. With a strong corporate philosophy centered around developing groundbreaking therapies for inflammatory and fibrotic diseases, Corbus Pharmaceuticals is committed to advancing medical science and making a positive impact in the healthcare industry. Through their research and development efforts, the company strives to provide effective and safe treatment options for patients worldwide. Corbus Pharmaceuticals Holdings Inc's unwavering commitment to excellence and their focus on delivering high-quality healthcare solutions make them a trusted name in the pharmaceutical industry.

Corbus Pharmaceuticals Holdings Inc is primarily present in the United States.

Corbus Pharmaceuticals Holdings Inc, a renowned pharmaceutical company, has achieved several significant milestones. One notable accomplishment was the successful completion of its Phase 2 clinical trial for lenabasum, its lead drug candidate, in the treatment of systemic sclerosis. The company also reached a major milestone by receiving Fast Track designation from the U.S. FDA for lenabasum in the treatment of dermatomyositis. Additionally, Corbus Pharmaceuticals initiated a Phase 3 clinical trial for its potential treatment in cystic fibrosis, highlighting their commitment to advancing innovative therapies. With these achievements, Corbus Pharmaceuticals continues to demonstrate its dedication to improving patients' lives through groundbreaking research and development.

Corbus Pharmaceuticals Holdings Inc. is a biopharmaceutical company founded in 2009. Headquartered in Norwood, Massachusetts, the company focuses on developing and commercializing innovative drugs to treat inflammatory and fibrotic diseases. Corbus Pharmaceuticals is dedicated to improving the lives of patients with rare, chronic, and severe diseases. With a strong emphasis on research and development, the company has pioneered a unique drug development platform targeting the endocannabinoid system. Through its novel drug candidates, including lenabasum, Corbus Pharmaceuticals aims to address unmet medical needs and provide promising treatment options for patients worldwide.

The main competitors of Corbus Pharmaceuticals Holdings Inc in the market include pharmaceutical companies such as Gilead Sciences Inc, AbbVie Inc, and Amgen Inc.

Corbus Pharmaceuticals Holdings Inc primarily operates in the biotechnology and pharmaceutical industries.

The business model of Corbus Pharmaceuticals Holdings Inc is focused on the development and commercialization of innovative therapeutics to address unmet medical needs. The company primarily focuses on developing therapies that target inflammatory and fibrotic diseases. Corbus Pharmaceuticals aims to provide effective treatment options for patients suffering from serious conditions such as systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus, among others. By leveraging its expertise in drug discovery and development, Corbus Pharmaceuticals aims to bring novel treatments to market that can improve patients' quality of life and potentially reshape the standard of care in these therapeutic areas.

Corbus Pharmaceuticals Holdings KGV ir -1,90.

Corbus Pharmaceuticals Holdings KUV ir 0.

AlleAktien kvalitātes vērtējums Corbus Pharmaceuticals Holdings ir 5/10.

Pašreiz nevar aprēķināt apgrozījumu Corbus Pharmaceuticals Holdings.

gaidāmā Corbus Pharmaceuticals Holdings peļņa ir -44,43 milj. USD.

Corbus Pharmaceuticals Holdings Inc is a biopharmaceutical company specializing in the development and marketing of novel medications for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Norwood, Massachusetts and has been listed on NASDAQ since 2014. The company focuses on developing medications based on cannabinoids, specifically targeting the CB2 receptor. The CB2 receptor plays an important role in regulating the immune system and is a promising target for the treatment of inflammation and fibrotic diseases. Corbus has developed its own technology platform to identify and develop highly selective and highly effective CB2 agonists. Corbus Pharmaceuticals' extensive portfolio currently includes multiple clinical phase 3 programs and clinical phase 2 programs in various indications, including the rare fibrotic disease idiopathic pulmonary fibrosis, systemic sclerosis, and dermatomyositis. In addition, the company is also developing medications for the treatment of other inflammatory and fibrotic diseases, including rheumatoid arthritis and cystic fibrosis. Corbus follows an integrated business model that focuses on internal research and development, as well as collaboration with strategic partners and acquisitions. The company has formed several partnerships with renowned academic institutions and scientists to expand and diversify its portfolio. Currently, the company does not offer any direct product offerings as all medications are still in the developmental phase. However, Corbus works closely with regulatory authorities and approval bodies to obtain market approvals for its medications in order to help patients as soon as possible. In doing so, the company aims to establish a strong market position in a highly dynamic and promising segment of the biopharmaceutical industry. So far, the results are promising, and the company sees good opportunities to address the underlying inflammatory and fibrotic diseases. Overall, Corbus Pharmaceuticals is an innovative biopharmaceutical company with a promising portfolio of potential therapeutics. The company relies on solid internal R&D development, as well as strategic collaboration with renowned academic institutions to expand its portfolio. Corbus aims to develop medications that positively impact the lives of patients with inflammatory and fibrotic diseases and improve the underlying disease mechanisms.

Corbus Pharmaceuticals Holdings izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Corbus Pharmaceuticals Holdings vai uzņēmums nedod dividendes.

Corbus Pharmaceuticals Holdings ISIN ir US21833P1030.

Corbus Pharmaceuticals Holdings WKN ir A14R7P.

Corbus Pharmaceuticals Holdings simbols ir CRBP.

Pēdējo 12 mēnešu laikā Corbus Pharmaceuticals Holdings maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Corbus Pharmaceuticals Holdings plāno maksāt dividendes 0 USD apmērā.

Corbus Pharmaceuticals Holdings pašreizējā dividendu rentabilitāte ir .

Corbus Pharmaceuticals Holdings maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Corbus Pharmaceuticals Holdings pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Corbus Pharmaceuticals Holdings tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Corbus Pharmaceuticals Holdings apmērā 0 USD, kas tika izmaksāta 22.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 22.09.2024..

Pēdējās dividendes izmaksa notika 22.09.2024..

Gadā 2023, Corbus Pharmaceuticals Holdings izmaksāja 0 USD dividendes.

Corbus Pharmaceuticals Holdings dividendes tiek izmaksātas USD.